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Abstract Migraine is a common disease which causes
significant burden to individuals, in terms of personal
suffering and activity reduction, and to societies, in terms
of disease cost. The purpose of this study is to identify the
most relevant psychosocial difficulties related to migraine,
the variables associated with them and the most relevant
determinants of their evolution over time. MEDLINE and
PsychINFO were searched for studies published in English
between 2000 and 2010 that examined psychosocial diffi-
culties in persons with migraine with and without aura,
from clinical trials and observational studies. Information
on the description of each difficulty, its determinants of
onset and change over time and associated variables were
extracted and categorized at a higher level. In total, 34
difficulties have been collected from 51 papers: the most
frequent were reduced vitality and fatigue, emotional
problems, pain, difficulties at work, general physical and
mental health, social functioning and global disability.
Evidence exists that pharmacological treatments have an
impact toward improvement in patients’ difficulties,
in particular emotional problems, physical and mental
health, difficulties with employment and global disability.
Migraine treatments and decreased headaches frequency
are the major determinants of improvements in psychoso-
cial difficulties, while no information is available for
determinants of worsening; understanding the role of such
factors is of primary public health relevance, given the high
prevalence and the relevant personal and societal costs of
migraine.
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Introduction
Migraine prevalence is around 15 % (17.6 % in women) in
European Countries [1, 2], and its average annual cost per
patient is estimated at 1,222€, of which 93 % are indirect
costs related to reduced productivity and absenteeism [3].
Migraine adversely affects patients’ health-related quality
of life (HRQoL), independently from comorbidities such as
mood or anxiety disorders [4–7], and contributes to several
difficulties in daily life. Because of this, the World Health
Organization (WHO) recognizes migraine as a high prior-
ity public health problem [8].
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The impact of migraine on patients’ daily life has been
assessed using measures of disability, activity limitation or
HRQoL, often as secondary measures of treatment out-
come [4–7, 9, 10]. Disability associated with migraine is
strictly related to its severity: areas of functioning such as
communication, mobility, self-care, participation in soci-
ety, relationships with others [11] and with family mem-
bers [12] are particularly affected. Yet, the difficulties
experienced by patients have never been systematically
described in a literature review that looks at their impact
both at the personal and societal levels. To our knowledge,
only factors related to gender differences have been ana-
lyzed in a review [13]: there the authors concluded that
gender and social role expectations, as well as coping
strategies, are different and this determines differences in
response to pain. However, no information on course and
determinants of these difficulties was included in this
review, which is an important gap if we are to reduce the
indirect effects of migraine on patients’ daily lives.
We therefore propose a systematic literature review of
the psychosocial difficulties (PSDs) associated with
migraine. For our purposes, PSDs are understood in terms
of the biopsychosocial model found in the International
Classification of Functioning, Disability and Health (ICF)
[14]. According to this model, PSDs are impairments of
mental functions and activity limitations and participation
restrictions that involve social interactions, such as in work,
family life and leisure activities, as well as daily activities
such as those connected to daily routing, homework or
mobility. Since these difficulties account for the personal
and socio-economic burden of migraine, it is important to
identify and understand the impact of those factors that are
responsible for the onset and course of PSDs.
The aims of this review are twofold. First, to system-
atically identify the range of PSDs reported in the literature
on migraine; second, to identify the most relevant deter-
minants of onset and change over time for PSDs, as well as
the variables that are associated with these PSDs. Since
PSDs are defined according to the ICF’s biopsychosocial
model, the literature review will be organized according to
the ICF classification structure.
Methods
Search strategy
MEDLINE and PsychINFO were searched for studies
published in English between January 2000 and May 2010
that examined PSDs in persons with migraine. Ten years
enabled us to focus on current treatment strategies—i.e.,
the established use of triptans and of preventive medica-
tions—which have had an impact on PSDs, and to find
studies published during a period in which the issue of the
burden of brain disorders is topical.
Search terms were customized to each database by
combining the term migraine with the following key words:
psychosocial*, Quality of Life/, Personal Satisfaction/, exp
Human Activities/and exp Social Support/disabilit*,
homelessness, environmental factor*, exp Interpersonal
Relations/, Quality of Life/, Personal Satisfaction/, exp
Human Activities/, paternalism/, prejudice/, psychosocial
deprivation/, social values/, exp Social Problems/, Social
Adjustment/, social isolation/, stereotyping/, exp Social
Environment/, exp emotions/, exp family/, exp socioeco-
nomic factors/, exp life style/, exp Disability evaluation/,
Communication Barriers/, Adaptation, Psychological/,
Aggression/, Psychological stress/, (community not micro-
bial community), or (sexual* or intimacy).
Paper inclusion and exclusion criteria
Studies were included if patients were diagnosed with
migraine with or without aura, according to the criteria of
the International Headache Society’s classification, first
[15] or second [1] edition. Studies were excluded if at least
50 % of patients had comorbidities for substance abuse,
epilepsy, secondary headaches, cerebrovascular diseases or
reported more than 15 headaches/month.
Journal articles in English reporting randomized con-
trolled trials, controlled clinical trials, observational stud-
ies, and economic evaluation studies were included. In case
of multiple publications dealing with the same data, the
paper published in the journal with the highest impact
factor was included. Papers were excluded if they were
primary prevention studies, phase I and II studies, ecologic
studies, systematic reviews, case report/case series, quali-
tative studies and psychometric studies (development or
validation of questionnaires or scales), commentaries, let-
ters to the editors, editorials and conference reports. Since
we were particularly looking for determinants of PSDs over
time, longitudinal designs were of primary interest. Cross-
sectional studies were included if the content of the paper
was judged to be of primary importance for the identifi-
cation of relevant PSD or their associated variables. Other
exclusion criteria were the absence of psychosocial factors,
focus on caregivers’ burden, focus on risk factors leading
to migraine and not to PSD.
Paper selection and data extraction
Abstracts of papers that were selected from database
searches were screened by two experienced researchers
(AR and AMG). To insure quality and consistency of data
extraction, 20 % of the abstracts were randomly selected
for a second check by another reviewer (RQ) who was
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blinded to the decisions of the first two. Each reviewer had
to rate the paper as excluded, eligible or ambiguous. Full
texts of papers that were judged eligible or ambiguous were
then analyzed, and 10 % of the full texts were double
checked by two reviewers independently. An evaluation of
the paper’s quality was performed using the National
Institute for Health and Clinical Excellence guidelines
[16], and the quality of the study was judged poor (1),
acceptable (2), good (3) or excellent (4): papers with poor
quality were excluded. For practical reasons, quality scores
will be reported at a group level only.
Extracted information was referred to the description of
each PSD, the determinants of their onset or change over
time, as well as other variables associated with PSDs.
Determinants of change over time were extracted exclu-
sively from longitudinal studies; variables associated with
PSDs were collected from cross-sectional studies or from
cross-sectional analysis in longitudinal studies. Information
on study design, type of intervention and characteristics of
the study population were extracted as well.
Information synthesis was a three-step process. First,
collected PSDs—extracted exactly as they were presented
in each paper—were grouped into categories based on the
ICF classification according to standardized ICF linking
rules [17]. ICF linking is an established procedure requir-
ing the content of items in assessment instruments to be
connected to the most precise ICF category possible:
training was provided for this procedure and 10 % of full-
text were double checked with regard to linking results.
The ICF categories representing the PSDs were then
grouped by similarity of content into overarching catego-
ries according to Popay’s guidelines [18] on how to ana-
lyze narrative reviews. Finally, following a methodology
recently employed by Cabello et al. [19], evidence was
judged as strong if there were at least two good papers
reporting the same results; limited if there was only one
good paper and some acceptable studies reporting similar
result; controversial in case studies reported contrasting
results.
Results
In total, 627 abstracts were screened (Fig. 1): 492 records
were excluded at abstract screening, mainly because they
did not include a measure of PSD consistent with selection
criteria or because the main health condition was not
migraine. Therefore, 136 full texts were read, after which
84 papers were excluded: these exclusions were mainly due
to a poor measurement or conceptualization of PSDs,
inadequacy of research design or the presence of comor-
bidities. Therefore, 51 papers were included in the syn-
thesis [20–70].
Table 1 reports the major characteristics of included
studies. Sample sizes were heterogeneous and varied
between 12 and 5,417. Percentage of females was reported
in 46 studies and ranged between 43.8 and 100 %, with a
mean of 80.2 %. Information about age was reported in 48
papers and ranged between 12 and 88 years, with an
aggregate mean age of 40.6 years. Disease duration,
reported either as years from the onset of migraine or years
since diagnosis was reported in 14 studies, with a mean of
13.0 years. The mean quality of studies was 2.7, median 3,
i.e., generally good.
Table 2 reports the span of PSDs found in included
studies: in total, 34 different PSDs have been collected and
these have been reported 231 times, mostly from ran-
domized trials (91 times) and longitudinal observational
studies (63 times). Due to the amount of PSDs collected,
only those addressed at least ten times are described in
detail. These were problems with energy and drive func-
tion, emotional functions and sensation of pain; difficulties
with remunerative employment; general evaluations of
mental health and physical health, social functioning and
global disability evaluations.
Table 3 reports information on the determinants of
course over time and the variables associated with the most
frequently addressed PSDs. Variables related to mental
functions were generally reported as associated with PSDs,
and in some cases these variables are PSDs themselves.Fig. 1 Flowchart of paper selection
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With regard to the determinants of change over time, only
determinants of improvement were found: most of the
determinants referred to treatments, duration and frequency
of headaches and the presence of pain. Pain was also found
to be a determinant of PSD onset in two studies: in the first, it
was found to be a determinant of fatigue and problems with
perceptual and cognitive functions [20]; in the second, it was
found to be a determinant of difficulties with employment,
both reduced efficiency and reduction in time [21].
Energy and drive functions
This set of functions includes in particular fatigue and
vitality, which represent 6.9 % of all PSDs. There is strong
evidence of the association of fatigue and headache pain
[20, 22], while the evidence is limited for the association
between decreased motivation and headache duration [22],
and between reduced vitality, headache frequency [23],
general emotional problems [24] and reduced work effi-
ciency [20]. Limited evidence also exists for the associa-
tion between reduced vitality and fatigue, low general
health [22] and increased disability [25, 26].
Strong evidence exists that pain reduction [27, 28] and
decreased headache frequency [20, 29, 30] positively affect
patients’ vitality. Limited evidence exists that symptomatic
medications, such as Almotriptan [26] and Rizatriptan [31],
improve patient vitality. Limited evidence also exists about
the utility of Topiramate in improving vitality [32] and
reducing fatigue [33] as well as of other prophylactic
agents, including antiepileptics, antidepressants, neurolep-
tics, and beta-blockers in improving vitality [29].
In sum, there is strong evidence that problems with
fatigue and reduced vitality were associated with the
presence of pain and that pain reduction and decreased
headache frequency determine improvement in vitality,
while there is limited evidence for the association between
vitality, work efficiency, general health and disability. The
evidence of prophylactic and symptomatic medications
effect toward the improvement of vitality and fatigue
reduction is limited.
Emotional functions
A relevant part of identified PSDs refers to emotional
problems, in particular anxiety and depressive mood, as
well as anger, stress, concerns about the disease, sense of
inadequacy and fear of migraine attacks. Taken as a whole,
these issues represent 23.3 % of all PSDs, with anxiety and
depressive mood being the most commonly addressed
(6.9 % each).
Limited evidence exists concerning the association
between anxiety and depressive mood and sleep problems
[34], the association between depressive mood, anger,
stress and anxiety, and between reduced vitality, fatigue,
patient general health state and reduced participation to
social activities [22]. In a population study, persons with
migraine had higher depression and anxiety compared to
healthy subjects: there is limited evidence that patients who
were aware of their condition reported slightly better scores
[35]. Limited evidence exists on the association between
migraine frequency and anxiety [36], while there is strong
evidence that general emotional problems are associated
with increased disability [26] and reduced HRQoL [37].
Limited evidence exists about the positive impact of
stress reduction and improvement of depressive mood and
anxiety [38], while strong evidence exists on the effect of
pain reduction toward improvement in general emotional
problems [27] and anxiety [39]. Limited evidence exists
about the role of migraine frequency: patients with less
frequent headaches reported lower anxiety levels [40], and
Table 1 General characteristics of included studies












Total sample size 5,155 7,147 471 1,051 7,004 20,852
Mean ± SD 572.8 ± 841.1 595.6 ± 1,526.8 235.5 ± 191.6 210.2 ± 350.4 304.5 ± 358.1 401.0 ± 839.7
Min.–max. 28–2,245 20–5,471 100–371 20–835 12–1,506 12–5,471
Females (%) 82.2 80.7 84.7 86.1 77.5 80.2
Mean age (years) 41.1 41.2 36.9 39.6 39.9 40.6
Mean disease duration 13.6 12.1 18.9 – 18.2 13.0
Diagnosis
Migraine with aura (%) 4 5.1 14 29.6 26.2 9.8
Migraine without aura (%) 96 94.9 86 70.4 73.8 90.2
Overall quality (mean ± SD) 2.4 ± 0.5 2.4 ± 0.5 3 ± 0 2.4 ± 0.5 2.9 ± 0.7 2.7 ± 0.7
Percentages, mean age, mean disease duration were calculated in reference to the number of patients enrolled for each study type
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Table 2 Psycho-social difficulties identified in included studies categorized according to ICF structure



















B130: Energy and drive
functions
Vitality 2 (4.3 %) 5 (7.9 %) – 1 (5 %) 4 (4.4 %) 12 (5.2 %)
Fatigue 1 (2.1 %) 1 (1.6 %) – – 1 (1.1 %) 3 (1.3 %)
Motivation – 1 (1.6 %) – – – 1 (0.4 %)
B134: Sleep functions Sleep 1 (2.1 %) – 1 (10 %) – 3 (3.3 %) 5 (2.2 %)
B140: Attention functions Cognitive functions:
attention
2 (4.3 %) – – – 1 (1.1 %) 3 (1.3 %)
B144: Memory functions Cognitive functions:
memory
1 (2.1 %) – – – – 1 (0.4 %)
B152: Emotional functions General emotional
functions
2 (4.3 %) 3 (4.8 %) – 1 (5 %) 7 (7.7 %) 13 (5.6 %)
Depressive mood
and symptoms
4 (8.5 %) 4 (6.3 %) 2 (20 %) 1 (5 %) 5 (5.5 %) 16 (6.9 %)
State anxiety 5 (10.4 %) 4 (6.3 %) 1 (10 %) 1 (5 %) 5 (5.5 %) 16 (6.9 %)
Trait anxiety – – 1 (10 %) – – 1 (0.4 %)
Stress 1 (2.1 %) 2 (3.2 %) – – 2 (2.2 %) 5 (2.2 %)
Anger 1 (2.1 %) 1 (1.6 %) – – 1 (1.1 %) 3 (1.3 %)
B156: Perceptual functions Perceptual functions 2 (4.3 %) – – – – 2 (0.9 %)
B280: Sensation of pain Pain 2 (4.3 %) 4 (6.3 %) – 1 (5 %) 4 (4.4 %) 11 (4.7 %)




– – – – 1 (1.1 %) 1 (0.4 %)
D240: Handling stress of other
psychological demands
Coping strategies 1 (2.1 %) 1 (1.6 %) – 1 (5 %) 2 (2.2 %) 5 (2.2 %)
D4: Mobility General mobility – – – – 3 (3.3 %) 3 (1.3 %)





1 (2.1 %) – – 1 (5 %) 2 (2.2 %) 4 (1.7 %)
D740: Formal relationships Relationships with
health professionals
1 (2.1 %) – – – – 1 (0.4 %)
D760: Family relationships Family relationships 1 (2.1 %) – – – – 1 (0.4 %)
D850: Remunerative
employment
Time restriction 2 (4.3 %) 1 (1.6 %) 1 (10 %) – 3 (3.3 %) 7 (3.0 %)
Reduced efficiency 1 (2.1 %) 2 (3.2 %) – 1 (5 %) 5 (5.5 %) 9 (3.9 %)
D920: Recreation and leisure Leisure activities 2 (4.3 %) 2 (3.2 %) 1 (10 %) – 2 (2.2 %) 7 (3.0 %)
Overall scores: linking to ICF
categories not determined
Mental health 2 (4.3 %) 5 (7.9 %) 1 (10 %) 2 (10 %) 5 (5.5 %) 15 (6.5 %)
Physical health 2 (4.3 %) 4 (6.3 %) 1 (10 %) 2 (10 %) 6 (6.6 %) 15 (6.5 %)
General health 2 (4.3 %) 3 (4.8 %) – – 1 (1.1 %) 6 (2.6 %)
Global functioning or
global disability
3 (6.4 %) 5 (7.9 %) – 3 (15 %) 15 (16.5 %) 26 (11.2 %)
Social functioning 2 (4.3 %) 4 (6.3 %) – 1 (5 %) 3 (3.3 %) 10 (4.3 %)
Quality of life – 3 (4.8 %) – 1 (5 %) 4 (4.4 %) 8 (3.5 %)
Role emotional 2 (4.3 %) 4 (6.3 %) – 1 (5 %) 1 (1.1 %) 8 (3.5 %)
Personal factors: not
linkable to ICF categories
Self-efficacy – 1 (1.6 %) – 1 (5 %) 1 (1.1 %) 3 (1.3 %)




– 1 (1.6 %) – – 3 (3.3 %) 4 (1.7 %)
Total number of PSD 47 (100 %) 63 (100 %) 10 (100 %) 20 (100 %) 91 (100 %) 231 (100 %)
J Headache Pain (2012) 13:595–606 599
123
those who underwent a reduction of headache frequency
had an improvement in anxiety and mood level [41, 42],
also in association with a good sense of self-efficacy [41].
Consistently strong evidence was found for the positive
effect of prophylactic and symptomatic medications. Pro-
phylactic therapies, such as Topiramate [32, 43], Ami-
triptyline [43] and Botulinum Toxin type A [33], or
symptomatic therapies such as Sumatriptan [22, 42] or
Almotriptan [26], determine a reduction of headache fre-
quency and intensity but also provide beneficial effects on
the reduction of emotional problems associated with
migraine, in particular low mood and anxiety [33]. Two
studies report limited evidence that complementary non-
medical treatments, such as massage therapy [44] and yoga
[45], determine a reduction of anxiety and mood problems.
In sum, there is limited evidence for the association of
emotional problems, in particular anxiety and depressive
mood and factors such as low vitality and fatigue. There is
also evidence, although limited, that headache frequency
decrease and complementary/alternative treatments have a
direct positive effect on anxiety and mood. Finally, there is
strong evidence that prophylactic and symptomatic medi-
cation have an impact on the reduction of emotional
problems.
Table 3 Variables reported as associated and determinants of improvement of the most frequently addressed PSDs























Depressive mood and symptoms A (1) A (1)
General emotional functions A (1) A (1) A (1)
Energy and drive A (4)








D? (1) A (1)
D? (1)
D? (1)
Self-efficacy D? (2) D? (1)










D? (2) D? (1) D? (2) A (1)
D? (3)
D? (2) D? (3)
Being aware of migraine A (2) A (1)
Treatment
Symptomatic D? (2) D? (3) D? (2) D? (4) D? (1) D? (1) D? (2) D? (5)
Prophylactic D? (2) D? (5) D? (2) D? (2) D? (2) D? (4) D? (2) D? (6)
Complementary/alternative D? (3) D? (1)
Psychological therapy D? (1)
Surgery D? (1) D? (2) D? (2) D? (3)
Multidisciplinary care D? (1) D? (1) D? (1)
Overall quality of life A (1) A (1) A (1)
General health A (2) A (3) D? (1)
Global functioning or disability A (2) A (1) A (1) A (1) A (1) A (1) A (1)
Passage of time D? (1) D? (1)
The number between brackets indicates the frequency of determinants and associated variables
A Variables associated with PSDs; D? variables acting as determinants of improvements of PSDs
a Pain was reported also as a determinant of onset of problems with fatigue in one study
b Pain was reported also as a determinant of onset of difficulties with remunerative employments—reduced efficiency and time restriction—in
one study
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Pain
Pain is the cardinal symptom of migraine but, despite this,
it has been directly considered as a PSD in a relatively
small number of paper (4.7 % of all PSDs), with a poor
pattern of association to global disability [25].
Limited evidence exists about the positive impact of
prophylactic medications, such as Topiramate [32] and
Botulinum Toxin type A [33], and symptomatic medica-
tions, such as Rizatriptan [31], Sumatriptan and Naproxen
Sodium [42] on pain reduction.
Employment
Difficulties in employment represent 6.9 % of all PSDs and
were mostly conceptualized as reduced efficiency and
restriction in time devoted to work, i.e., partial absence or
missed workdays.
Limited evidence exists on the association of time
restriction with overall HRQoL [25], and with global dis-
ability and the presence of pain [26]. Limited evidence is
available for the effect of pain reduction on improved work
efficiency [27, 46], and of reduced headache frequency on
decreased number of lost workdays [30]. Strong evidence
exists on the effect of symptomatic medication such as
Almotriptan [26], Rizatriptan [31], Sumatriptan [47] and
Eletriptan [48] on improving work efficiency. Strong evi-
dence also exists on the effect of prophylactic medications,
such as Botulinum Toxin type A and improved efficiency
[33], as well as of Topiramate/Amitriptyline and reduction
of missed workdays [43].
In sum, problems in employment represent a difficulty
both because of reduction in efficiency and restriction in
time. The pattern of association is scarcely determined,
while reduction of pain and prophylactic and symptomatic
medications was reported as a determinant of improvement
in workplace efficiency and reduction of missed workdays.
General physical and mental health
General descriptions of mental and physical health con-
stitute 6.5 % of all PSDs each, share a similar pattern of
association and are also affected by the same determinants
of improvement.
Limited evidence exists that poor mental health is
associated with general emotional problems [24] and that
both mental and physical health are associated with
depressive mood [37] and overall disability [25]. Limited
evidence also exists that low physical health is associated
with headache frequency [23].
Strong evidence exists that mental and physical health
improve consistently with reduction of headache frequency
[23, 29, 30], while the evidence of improvement in
physical health as a consequence of pain reduction is
limited [28]. There is also limited evidence that symp-
tomatic treatment with Rizatriptan is effective in improving
both physical and mental health [31]. With regard to pro-
phylactic treatment, strong evidence exists that Topiramate
is effective in improving both mental and physical health
[24, 32, 49], while the evidence of the effect of beta-
blockers such as Nebivolol and Metoprolol in improving
physical health is limited [50]. Improvement in both
physical and mental health after a surgical approach
(deactivation of peripheral migraine headache triggers) was
documented in two studies, but the evidence is limited [51,
52].
In sum, limited evidence exists that physical and mental
health are associated with emotional problems, headache
frequency and to overall disability. Strong evidence exists
that prophylactic treatment with Topiramate and reduced
headache frequency improve physical and mental health,
while the evidence of the effect of pain reduction, utiliza-
tion of Rizatriptan, beta-blockers as well as surgical
approaches is limited.
Social functioning
Issues of social functioning, in general, represent 4.3 % of
all PSDs. Problems in this area have been weakly associ-
ated with general emotional problems [24], HRQoL [25],
disability and the presence of pain [26].
Limited evidence exists about the positive effect of pain
reduction [28] and decreased headache frequency [29, 30]
in improving social functioning. Consistent but limited
evidence also exists about the effect of both symptomatic,
such as Almotriptan [26] and Rizatriptan [31], and pro-
phylactic medication, such as Topiramate [32] and Botu-
linum toxin type A [33] to improve social functioning.
Global disability
The concept of global disability implicitly encompasses all
the PSDs a person may experience in relation to migraine.
PSDs were frequently reported at this global level (in
11.2 % of the cases), which is the single most frequently
reported category.
Limited evidence exists that global disability is associ-
ated with poor subjective sleep quality [34] and with self-
awareness of migraine [35].
Limited evidence exists that patient disability is posi-
tively influenced by decreased headache frequency [23, 41,
53]. With regard to treatments, limited evidence exists
that symptomatic medication, such as Sumatriptan [42, 47],
Naproxen Sodium [42] Zolmitriptan [54] and Eletriptan
[48] have an impact on disability reduction. Strong
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evidence is instead reported by studies documenting
improvements due to prophylactic medication such as
Topiramate [32, 43, 49, 55, 56], Botulinum Toxin type A
[33], subcutaneous histamine [56], beta-blockers such as
Nebivolol and Metoprolol [50] and Amitriptyline [43].
Limited evidence is available for the effect of pain reduc-
tion, achieved through physical exercise, on disability
reduction [57]. There is limited evidence of the effect of
surgical approaches—deactivation of peripheral migraine
headache triggers [51, 52] and interatrial shunt closure
[58]—on disability improvement. Limited evidence also
exists that disability improves after the administration of a
home-based behavioral training [59], and as a consequence
of self-efficacy improvement, obtained with a self-admin-
istered behavioral intervention [41]. There is limited evi-
dence that a multidisciplinary intervention aimed to reduce
pain (sessions of exercise therapy, stress management ses-
sions, relaxation therapy, dietary lectures and massage
therapy sessions) was also effective in disability reduction
[60]. Finally, limited evidence was found for the effect of
passage of time [61].
In sum, general evaluation of disability was the most
commonly evaluated PSDs category found in the present
review. Reduction of disability in general is positively
associated with the effectiveness of treatment: the evidence
is limited for the effectiveness of symptomatic medica-
tions, behavioral interventions, surgical approaches and
physical exercise, while it is stronger for the effectiveness
of prophylactic medications.
Discussion
This review offers an overview of the PSDs reported in the
literature on migraine, the variables associated with them
and the determinants that influence their onset and course.
The most frequently studied PSDs were related to eight
areas: emotional problems, reduced vitality and fatigue,
pain, difficulties at work, reduced physical and reduced
mental health, poor social functioning and increased global
disability. A few variables were identified as associated
with a handful of PSDs, namely global disability, emo-
tional problems, pain and headaches frequency. On the
contrary, there is more evidence that migraine-specific
treatments improve emotional problems, physical and
mental health, difficulties with employment and global
disability. We found no studies evaluating possible deter-
minants of worsening of PSDs and the presence of pain
only was identified as a determinant of PSD onset.
To our knowledge, there is no previous attempt to sys-
tematically address PSDs relevant to migraine patients
according to a definition based upon the ICF. A previous
review [13] provided evidence that gender and social role
expectations, as well as coping strategies, are different and
this determines differences in response to pain. In our
review, we expanded the scope of problems reported by
migraineurs, and added information on the course and
factors that influence the improvement of these difficulties.
Our results also cast light on the conceptualization of dis-
ability found in migraine studies. The Migraine Disability
Assessment Schedule (MIDAS) [71] is a reference point to
assess disability in migraineurs and is used in the majority
of publications dealing with outcome of migraine. How-
ever, it covers only a small part of the entire burden of
living with migraine. A major result of our study was the
focus on several areas that may be relevant to describe the
problems experienced by patients with migraine, and that
we believe should be investigated.
The determinants of improvement identified here can be
roughly divided in two areas. The first includes variables
referred to features of the disease itself, e.g., frequency of
headaches and presence of pain. In general, limited evi-
dence was found for the effect of these determinants,
although they covered the full span of PSDs. The observed
trend acknowledges that reduced headache frequency and
pain decrease have a positive effect on improvement in
vitality and fatigue—for which strong evidence was
derived—emotional problems, physical and mental health,
social functioning, work ability and global disability. The
second area deals with prophylactic and symptomatic
treatments. Studies on symptomatic medication herein
included were focussed on different kinds of triptans rather
than anti-inflammatory agents, and there is strong evidence
that these medications determine an improvement in
emotional problems and work efficiency. However, the
most important determinants of PSD improvement found in
this literature review were prophylactic medications, and
there is strong evidence that these medications positively
affect emotional problems, improve work efficiency, global
disability, physical and mental health.
While several pharmacological studies have been pub-
lished in the past years, limited data exist on non-phar-
macological treatments. There is only sparse evidence on
the effect of complementary treatment and psychological
therapy: two studies showed efficacy of massage therapy
and yoga for the improvement of anxiety and mood prob-
lems [44, 45], while one study found that home-based
behavioral training might be effective to improve patient
functioning [59]. The fact that such non-pharmacological
interventions did not frequently occur in this literature
review is in part due to the search strategy that gave pri-
mary relevance to longitudinal intervention studies, i.e.,
clinical trials of acute or prophylactic medication. Surgery
is not a common procedure for migraine, rather it is indi-
cated for the treatment of chronic cluster headache [72] and
there are few experience on its use to treat patients with
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drug-resistant chronic migraine [73] also with comorbidity
to depression [74]. As a consequence, the extent to which
non-pharmacological treatments might improve migrai-
neurs’ difficulties is still an open question that should be
addressed in future research.
The articles included in the present review were mostly
reports of clinical trials, which provided a strong control
over study variables. In daily practice, however, clinicians
have to deal with acceptance and adherence to treatment,
which is a relevant issue for both prophylactic and acute
migraine treatments [75–77]. Among migraineurs, the issue
of non-adherence to treatment may have different impli-
cations, varying from inadequate timing in taking triptans,
to not accepting prophylactic medications, to the overuse
of symptomatic ones. Medication overuse, jointly with
comorbidity to mood problems [78, 79], might determine
worse health outcomes. In fact, problems with adherence to
migraine treatment might be further on amplified by low
treatment adherence which in mood disorders is around
40 % [80]. Multidisciplinary treatment has been proposed
as a strategy for improving adherence to treatment, but
results are conflicting [60, 81–83]. The implication of this
is that our results mostly report facts that have been gen-
erated in the ideal contexts of clinical trial, but the situation
of patients in real-life settings might be quite different.
Headache frequency is a determinant that deserves a
separate comment. Frequency was found to be associated
with the most relevant PSDs, but with strong evidence only
for improvements in vitality, physical and mental health. It
should be pointed out that reduction of headache fre-
quency—which is not a PSD itself—is generally the pri-
mary endpoint (for e.g., in clinical trials on the use of
prophylactic medications), while PSDs such as vitality
were viewed as secondary outcome measures. Considering
the aim and the methodology of the present review, the
implication of this fact is that we are likely to underesti-
mate the causal relationship between the treatment inter-
vention tested in clinical studies, the magnitude of their
effect on primary endpoints, and the improvements in
PSDs that we focus in this review.
Some limitations of this study should be mentioned.
Even though our search was extensive, we cannot be sure
that all relevant articles were located. The fact that no
determinant of PSD worsening was found is likely to be
due to a publication bias, with studies that report negative
results not being published. Some aspects of the included
studies may have influenced our results, in particular the
fact that there is an over-representation of data derived
from the MIDAS [71] and the Short-Form 36 Health Sur-
vey (SF-36) [84]: taken together, they were used in 28 of
the 51 included studies. The MIDAS may provide indica-
tions of either global disability or problems with work,
household and leisure activities, which were herein
described as separate PSDs. Similarly, SF-36-derived data
were either reported as summary scores and therefore
described as general health scores, or as subscales (e.g.,
vitality and social functioning) and thus reported as sepa-
rate PSDs. Since these instruments are almost always used,
the same PSDs are almost always reported, so that infor-
mation about other PSDs are less frequently reported and
remain almost unknown. However, the representation of
PSDs associated with migraine is partial. The reason for
this is that while there is a homogeneity due to the amount
of data derived from MIDAS and SF-36, the number of
PSDs is not describable in a synthetic way if the purpose is
to avoid the reporting of known issues such as increased
disability and reduced quality of life. With our synthesis,
we tried to balance the opposite needs of being compre-
hensive and synthetic. Investigators in the field of migraine
are therefore encouraged to evaluate other kinds of daily
difficulties not included in commonly used instruments,
and to include outcome measures that are able to capture
the burden of migraine in a comprehensive way.
As we were interested to evaluate the course over time
and determinants of PSDs’ course over time and the
determinants of PSD change over time, we finally included
several clinical trials: this is likely to reduce the ecological
validity of our results, as subjects participating in clinical
trials are exposed to a situation that is not the same com-
monly found in daily clinical practice.
A comment is also needed for pain, which was reported
as a PSD in a relatively limited number of studies, e.g.,
when pain severity was directly assessed (for e.g., with the
visual analog scale contained in MIDAS). In other studies,
pain was considered to be a determinant, for example when
reduction in pain was not directly measured, but was used
to create groups of subjects for between-subjects analysis
(e.g., the percentage of subjects achieving pain relief or
experiencing pain reduction by a given timeframe follow-
ing the intake of a medication).
Finally, the heterogeneity across studies should also be
taken into account. The studies were very different with
respect to sample size, number and duration of follow-up as
well as study designs that provide different levels of con-
trol over confounding variables. Disease duration was
reported in a small number of studies, hence preventing the
evaluation of the effect of length of exposure to different
PSDs, which may be influenced by disease duration.
Conclusions
Our results confirm that migraine is a burdensome disease
and that migraineurs experience several PSDs, in particular
emotional problems, reduced vitality, pain, increased dis-
ability, difficulties with work, mental and physical health,
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social functioning. Our results also show that symptomatic
and prophylactic treatments, by decreasing headache fre-
quency and reducing pain, also determine a reduction in
patient difficulties, thus reducing the burden associated
with migraine. However, we know little about the factors
that determine the worsening of PSDs, and understanding
the role of these factors is essential for the development of
prevention programs focusing on the PSDs associated with
migraine. These actions might provide a wider under-
standing of the burden, personal and economic, associated
with migraine.
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